A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®)
Françoise Forette, Ravi Anand, George GharabawiVolume:
6
Year:
1999
Pages:
7
DOI:
10.1046/j.1468-1331.1999.640423.x
File:
PDF, 870 KB
1999